HK1136213A1 - 作為破損傷口癒合組合物的間隙連接蛋白抗體多核苷酸 - Google Patents

作為破損傷口癒合組合物的間隙連接蛋白抗體多核苷酸

Info

Publication number
HK1136213A1
HK1136213A1 HK10103066.1A HK10103066A HK1136213A1 HK 1136213 A1 HK1136213 A1 HK 1136213A1 HK 10103066 A HK10103066 A HK 10103066A HK 1136213 A1 HK1136213 A1 HK 1136213A1
Authority
HK
Hong Kong
Prior art keywords
wound healing
impaired wound
healing compositions
anticonnexin
polynucleotides
Prior art date
Application number
HK10103066.1A
Other languages
English (en)
Inventor
David L Becker
Colin R Green
Bradford J Duft
Original Assignee
Coda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics Inc filed Critical Coda Therapeutics Inc
Publication of HK1136213A1 publication Critical patent/HK1136213A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10103066.1A 2006-12-11 2010-03-23 作為破損傷口癒合組合物的間隙連接蛋白抗體多核苷酸 HK1136213A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87440406P 2006-12-11 2006-12-11
PCT/US2007/025446 WO2008073479A2 (en) 2006-12-11 2007-12-11 Anticonnexin polynucleotides as impaired wound healing compositions

Publications (1)

Publication Number Publication Date
HK1136213A1 true HK1136213A1 (zh) 2010-06-25

Family

ID=39386432

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103066.1A HK1136213A1 (zh) 2006-12-11 2010-03-23 作為破損傷口癒合組合物的間隙連接蛋白抗體多核苷酸

Country Status (16)

Country Link
US (5) US8063023B2 (zh)
EP (3) EP2543377A1 (zh)
JP (3) JP5431949B2 (zh)
KR (1) KR101521306B1 (zh)
CN (2) CN103520197B (zh)
AU (1) AU2007333535B2 (zh)
BR (1) BRPI0721094A2 (zh)
CA (1) CA2672220A1 (zh)
DK (1) DK2101791T3 (zh)
ES (1) ES2527131T3 (zh)
HK (1) HK1136213A1 (zh)
PL (1) PL2101791T3 (zh)
PT (1) PT2101791E (zh)
RU (1) RU2521329C2 (zh)
SI (1) SI2101791T1 (zh)
WO (1) WO2008073479A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080031154A (ko) 2005-02-03 2008-04-08 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
WO2008073479A2 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
WO2009075882A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
EP2628747A1 (en) * 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP2011507861A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
NZ612533A (en) * 2010-12-06 2015-03-27 Univ British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
GB201117538D0 (en) * 2011-10-11 2011-11-23 Royal Veterinary College The Methods
DK2819682T3 (en) 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
CN104736709A (zh) * 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP3116996A4 (en) * 2014-03-14 2018-01-10 Ocunexus Therapeutics, Inc. Treatment of resistant lesions
CN114010788A (zh) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
CN113694077A (zh) * 2015-08-13 2021-11-26 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
US11096832B2 (en) * 2016-09-27 2021-08-24 Smith & Nephew Plc Wound closure devices with dissolvable portions
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (zh) * 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
WO1998024797A1 (en) 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
RU2147240C1 (ru) * 1998-02-16 2000-04-10 Рязанский областной клинический кожно-венерологический диспансер Препарат для лечения длительно незаживающих инфицированных язв и ран
ATE533515T1 (de) * 1999-01-27 2011-12-15 Coda Therapeutics Inc Formulierungen enthaltend antisense nukleotide spezifisch für connexine
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
CA2461542A1 (en) 2001-10-17 2003-04-24 Tudor Morley Griffith Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
US7153822B2 (en) * 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
JP5838017B2 (ja) * 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
DK1827480T3 (en) 2004-12-21 2017-01-09 Musc Found For Res Dev FORMATIONS AND PROCESSES FOR PROMOTING WOUND HEALING AND tissue regeneration
KR20080031154A (ko) * 2005-02-03 2008-04-08 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
WO2008073479A2 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
EP2628747A1 (en) 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009075882A2 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Also Published As

Publication number Publication date
US8063023B2 (en) 2011-11-22
CN101835476B (zh) 2016-08-17
BRPI0721094A2 (pt) 2014-02-11
EP2101791B1 (en) 2014-09-10
US9029339B2 (en) 2015-05-12
RU2009126594A (ru) 2011-01-20
EP2543377A1 (en) 2013-01-09
US20150315598A1 (en) 2015-11-05
DK2101791T3 (en) 2015-01-05
WO2008073479A2 (en) 2008-06-19
WO2008073479A3 (en) 2008-08-07
CN101835476A (zh) 2010-09-15
ES2527131T3 (es) 2015-01-20
JP2015063565A (ja) 2015-04-09
RU2521329C2 (ru) 2014-06-27
KR20090118910A (ko) 2009-11-18
AU2007333535A1 (en) 2008-06-19
JP2013173796A (ja) 2013-09-05
AU2007333535B2 (en) 2014-04-17
US8685940B2 (en) 2014-04-01
JP5431949B2 (ja) 2014-03-05
US20120289579A1 (en) 2012-11-15
CN103520197A (zh) 2014-01-22
PL2101791T3 (pl) 2015-04-30
KR101521306B1 (ko) 2015-05-18
US20080242631A1 (en) 2008-10-02
EP2543378A1 (en) 2013-01-09
JP2010512404A (ja) 2010-04-22
PT2101791E (pt) 2014-12-18
CA2672220A1 (en) 2008-06-19
US9637745B2 (en) 2017-05-02
SI2101791T1 (sl) 2015-02-27
EP2101791A2 (en) 2009-09-23
US20170240905A1 (en) 2017-08-24
US20130143952A1 (en) 2013-06-06
CN103520197B (zh) 2017-11-21
JP5911454B2 (ja) 2016-04-27

Similar Documents

Publication Publication Date Title
HK1136213A1 (zh) 作為破損傷口癒合組合物的間隙連接蛋白抗體多核苷酸
HUS2000015I1 (hu) Fungicid készítmények
ZA200900240B (en) Antibacterial compositions
EP2124575A4 (en) ANTIMICROBIAL COMPOSITIONS
EP2040708A4 (en) CROSS-CONTAINING COMPOSITIONS
GB0624290D0 (en) Novel compositions
GB0624340D0 (en) Antimicrobial composition
GB0621023D0 (en) Fragrance compositions
GB0607085D0 (en) Novel compositions
IL193359A0 (en) Ezetimibe compositions
GB0625069D0 (en) Compositions
EP2097355A4 (en) ANTIMICROBIAL COMPOSITION
GB0620279D0 (en) Compositions
IL198651A0 (en) COMPOSITION COMPRISING (-)-Ôêå9-TRANS-TETRAHYDROCANNABIONOL
GB0618657D0 (en) Compositions
IL197235A0 (en) Therapeutic compositions
EP2059126A4 (en) ANTIMICROBIAL COMPOSITION CONTAINING ISOTHIAZOLIN-3-ONE
EP1986849A4 (en) COMBUSTION REMOVAL COMPOSITIONS, RESISTANT TO WASH
GB0621020D0 (en) Fragrance compositions
GB0620918D0 (en) Compositions
GB0619375D0 (en) Wound healing compositions
ZA200901574B (en) Topical compositions
EP2061445A4 (en) ANTIMICROBIAL COMPOSITIONS
GB0917779D0 (en) Novel compositions
GB0601899D0 (en) Compositions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201211